NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
3.500
-0.490 (-12.28%)
At close: Jun 27, 2025, 4:00 PM
3.680
+0.180 (5.14%)
After-hours: Jun 27, 2025, 4:04 PM EDT

Company Description

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.

Its lead product candidates include NEO100, a purified form of preillyl acid that is in clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors.

The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009.

NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is based in Calabasas, California.

NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings logo
Country United States
Founded 2008
Industry Biotechnology
Sector Healthcare
Employees 8
CEO Thomas Chen

Contact Details

Address:
23975 Park Sorrento, Suite 205
Calabasas, California 91302
United States
Phone 310-663-7831
Website neonctech.com

Stock Details

Ticker Symbol NTHI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001979414
ISIN Number US64051A1016
Employer ID 92-1954864
SIC Code 2834

Key Executives

Name Position
Dr. Thomas C. Chen M.D., Ph.D. Founder, Chief Executive Officer, Chief Scientific Officer and Director
Keithly A. Garnett Chief Financial Officer and Director
Amir Farrokh Heshmatpour President, Executive Chairman and Secretary
Dr. Josh Neman-Ebrahim M.D. Chief Clinical Officer

Latest SEC Filings

Date Type Title
Jun 16, 2025 EFFECT Notice of Effectiveness
Jun 16, 2025 424B5 Filing
Jun 12, 2025 8-K Current Report
Jun 6, 2025 S-1 General form for registration of securities under the Securities Act of 1933
Jun 6, 2025 8-K Current Report
Jun 3, 2025 8-K Current Report
May 9, 2025 10-Q Quarterly Report
May 6, 2025 EFFECT Notice of Effectiveness
May 6, 2025 424B5 Filing
May 2, 2025 UPLOAD Filing